EDAP TMS
EDAP TMS's revenue rose 1.6% to $70 million in fiscal 2025. Its operating margin was −35.0%, down from −32.0% a year earlier. The diluted share count rose 0.4%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
What EDAP TMS does
EDAP TMS is a French medical device company, founded in 1979 and based in Vaulx-en-Velin, that trades under the name Focal One. It makes machines that use high-intensity focused ultrasound, or HIFU, to destroy diseased tissue without cutting into the body. Its main product, the Focal One robotic HIFU system, lets urologists treat targeted areas of the prostate in men with prostate cancer while limiting harm to nearby tissue. It sells to hospitals and clinics in the United States, Europe, Asia and elsewhere.
It earns money from selling the machines and from the recurring sale of disposable parts used in each treatment and of maintenance services. The company has shifted its focus to HIFU and away from older lines, such as lithotripsy machines that break up kidney stones and other companies' urology products it distributes; it still sells and services these in some markets. It sells through its own teams and through distributors abroad.
Focal One has been cleared for prostate tissue treatment in the US since 2018 and in Europe since 2013. The company is running studies to use it for an enlarged prostate and for endometriosis, a painful condition in women; for the latter it has a European approval and an FDA Breakthrough Device designation. It makes its products at a single site in France.
Its biggest risks, as it describes them
- Doctors may not widely adopt HIFU, which may never become a standard treatment.
- Needing new financing, which may not be available when required.
- Health authorities and insurers may not pay for procedures using its products.
- Its clinical trials for new uses may fail or not lead to approval.
- Its dependence on a single manufacturing site and a few suppliers.
Income statement
EDAP TMS lost money in fiscal 2025: a net loss of $29 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | — | — | 48 | 31 | 20 |
| Debt incl. finance leases | — | — | — | 12 | 24 |
| Net debt (negative means net cash) | — | — | — | −19 | 4 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | 0.3x | 1.3x |
| Interest coverage | — | — | — | −86.8x | −31.3x |
| Current ratio | — | — | — | 1.9x | 1.5x |
| Quick ratio | — | — | — | 1.4x | 1.2x |
Cash flow
Free cash flow is cash from operations minus capital expenditure. The SEC's structured data for EDAP TMS's filings doesn't give both for any year, so free cash flow is left out.
Projections
Project EDAP TMS's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What EDAP TMS says to expect
- Full year 2026: revenue
We are narrowing our full-year 2026 revenue guidance to be in the range of $50.0 to $52.0 million, representing 34% to 39% growth over 2025, from the prior range of $50.0 to $54.0 million.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 4 insiders bought $450,700 of EDAP TMS shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 14, 2026 | Lance WillseyDirector | Bought | 50,000 | $4.75 | $237,500 | Form 4 |
| Aug 14, 2026 | Ryan RhodesChief Executive Officer, Director | Bought | 21,000 | $4.75 | $99,750 | Form 4 |
| Aug 14, 2026 | Joshua LevineDirector | Bought | 10,000 | $4.75 | $47,500 | Form 4 |
| Aug 14, 2026 | Steven AnnenSVP, Marketing & Product Mgmt. | Bought | 5,000 | $4.75 | $23,750 | Form 4 |
| May 11, 2026 | Joshua LevineDirector | Bought | 10,000 | $4.22 | $42,200 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | — | — | — |
| Altman Z'' | — | −1.90 | −5.40 |
| Accruals ratio | — | — | −15.2% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | — | — | Fail |
| Cash from operations is positive | — | Fail | Fail |
| Return on assets rose | — | — | — |
| Cash from operations exceeds net income | — | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | — | — | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | Pass |
| Revenue rose relative to assets | — | — | — |
| F-score | — | — | — |
Compare
Put EDAP TMS side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| EDAP TMS | FY25 | 1.6% | −35.0% | — | −83.4% | — | — | |
| AVITA Medical | FY25 | 11.4% | −59.4% | −45.0% | −354.1% | — | 2 | Compare |
| Electromed | FY26 | 15.3% | 18.8% | 11.4% | — | — | — | Compare |
| Sight Sciences | FY25 | −3.1% | −48.0% | −38.7% | — | — | 5 | Compare |
| Pro Dex | FY26 | 16.4% | 16.8% | 8.7% | 19.6% | 0.6x | 7 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | — | — | — | — | — | — | — | — | 69 | 70 |
| Revenue growth | — | — | — | — | — | — | — | — | — | 1.6% |
| Gross profit | — | — | — | — | — | — | — | — | 29 | 30 |
| Research and development | — | — | — | — | — | — | — | — | 8 | 10 |
| Operating income | — | — | — | — | — | — | — | — | −22 | −25 |
| Net income | — | — | — | — | — | — | — | — | −21 | −29 |
| Diluted EPS (US$) | — | — | — | — | — | — | — | — | −0.55 | −0.78 |
| Diluted shares (millions) | 29 | 29 | 29 | 30 | 29 | 32 | 34 | 37 | 37 | 37 |
| Cash flow | ||||||||||
| Cash from operations | — | — | — | — | — | — | — | — | −15 | −16 |
| Capital expenditure | — | — | — | — | — | — | — | — | — | — |
| Free cash flow | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | — | — | — | — | — | — | — | — | — | — |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | — | — | — | — | — | — | — | 48 | 31 | 20 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — | 12 | 24 |
| Total assets | — | — | — | — | — | — | — | — | 89 | 79 |
| Total liabilities | — | — | — | — | — | — | — | — | 47 | 60 |
| Shareholders' equity | — | — | — | — | — | — | — | 63 | 42 | 19 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | — | — | 41.4% | 42.5% |
| Operating margin | — | — | — | — | — | — | — | — | −32.0% | −35.0% |
| Net margin | — | — | — | — | — | — | — | — | −29.7% | −41.5% |
| Free cash flow margin | — | — | — | — | — | — | — | — | — | — |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | — | — | — | — | — |
| Return on capital | — | — | — | — | — | — | — | — | — | −83.4% |
| Return on equity | — | — | — | — | — | — | — | — | — | −94.5% |
| Return on assets | — | — | — | — | — | — | — | — | — | −34.7% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |